TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38273252

Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen plus acetaminophen
Number of subjects: 158

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 158
Study: 38273259

Group type: EXPERIMENTAL
Intervention: Wet clothing removal and wrapping in a vapor barrier, insulating blankets, and windproof outer shell (dry group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wrapping in a vapor barrier, insulating blankets, and windproof outer shell (wet group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 38273290

Group type: EXPERIMENTAL
Intervention: Patients with IPF
Number of subjects: 300
Study: 38273296

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - excitatory (20 min @ 10 Hz, applied to the lateral and medial pre-frontal cortex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - inhibitory (20 min @ 1 Hz, applied to the pelvic supplemental motor area)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract.
Number of subjects: 0
Study: 38273300

Group type: EXPERIMENTAL
Intervention: Patients perceived as dying
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Patients on the day of death
Number of subjects: 696

Group type: COMPARATOR
Intervention: Patients with dementia at admission
Number of subjects: 696
Study: 38273319

Group type: EXPERIMENTAL
Intervention: PLUS algorithm (clinical prediction score, lung ultrasound (LUS), procalcitonin (PCT), clinical severity score)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PLUS algorithm
Number of subjects: 10
Study: 38273369

Group type: EXPERIMENTAL
Intervention: Train-the-Trainer (TT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Train-the-Trainer plus ongoing consultation for trainers (TT +)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cost of implementation for TT
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cost of implementation for TT +
Number of subjects: 125
Study: 38273370

Group type: EXPERIMENTAL
Intervention: Consequences Of Screening Lung Cancer (COS-LC) questionnaire administered at prespecified timepoints including at enrolment, dependent on screening results.
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: COS-LC questionnaire
Number of subjects: 1129
Study: 38273379

Group type: EXPERIMENTAL
Intervention: Alantel cream (natural products at high concentrations)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Moisturizing cream (control)
Number of subjects: 88
Study: 38273393

Group type: EXPERIMENTAL
Intervention: Titrated oxygen delivery targeting a blood oxygen saturation of 88-92% during inhalation therapy
Number of subjects: 1888

Group type: COMPARATOR
Intervention: Standard high flow oxygen delivery
Number of subjects: 1888
Study: 38273390

Group type: EXPERIMENTAL
Intervention: Burnout during the pandemic measured by the Shirom-Melamed Burnout Measure
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Clinical and research activities during the pandemic
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Training resources during the pandemic
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Involvement in COVID-19 management
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: Burnout among trainees
Number of subjects: 954
Study: 38273408

Group type: EXPERIMENTAL
Intervention: 100 mg per day of oral CT1812 for 24 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 300 mg per day of oral CT1812 for 24 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: 100 mg or 300 mg per day of oral CT1812 for 24 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 38273436

Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis
Number of subjects: 0
Study: 38273597

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo (initially assigned)
Number of subjects: 219
Study: 38273617

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (1 min once daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (1 min four times daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham stimulation (device implanted but not activated)
Number of subjects: 14
Study: 38273624

Group type: EXPERIMENTAL
Intervention: JNJ-55920839 (0.3-15 mg/kg IV or 1 mg/kg SC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 38273625

Group type: EXPERIMENTAL
Intervention: Otilimab 180 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 38273637

Group type: COMPARATOR
Intervention: Tofacitinib 5 mg twice daily plus placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily plus methotrexate
Number of subjects: 180
Study: 38273639

Group type: EXPERIMENTAL
Intervention: Sirolimus 2 mg once daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 38273712

Group type: EXPERIMENTAL
Intervention: Extensive program
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Basic program
Number of subjects: 279

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 279
Study: 38274114

Group type: EXPERIMENTAL
Intervention: 10 or 100 μg rTSST-1v
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 100 μg rTSST-1v
Number of subjects: 140

Group type: COMPARATOR
Intervention: Al(OH)
Number of subjects: 140
Study: 38274233

Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal surgery (EES)
Number of subjects: 211
Study: 38274236

Group type: EXPERIMENTAL
Intervention: ARNI
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: SGLT2i
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Combination treatment (ARNI + SGLT2i)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: ARNI (alone)
Number of subjects: 539
Study: 38274292

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) administered to the left dorsolateral prefrontal cortex (DLPFC) for 14 days every 13 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 42
Study: 38274389

Group type: EXPERIMENTAL
Intervention: 25 Gy SCRT in five fractions
Number of subjects: 172
Study: 38274398

Group type: EXPERIMENTAL
Intervention: Velacur®
Number of subjects: 143
Study: 38274414

Group type: EXPERIMENTAL
Intervention: SPL026 (21.5 mg) administered as a 2-phase IV infusion over 10 minutes (6 mg/5 min and 15.5 mg/5 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38274492

Group type: EXPERIMENTAL
Intervention: TAF 25 mg/day with selgantolimod 3 mg orally once weekly (QW)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Selgantolimod 1.5 mg QW
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 38274807

Group type: EXPERIMENTAL
Intervention: Radical concurrent chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy, followed by adjuvant immunotherapy for at least one year.
Number of subjects: 0
Study: 38274885

Group type: EXPERIMENTAL
Intervention: Wearable home-use gait device (iStride), 12 sessions of 30 minutes each
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Wearable home-use gait device (iStride)
Number of subjects: 18
Study: 38275115

Group type: EXPERIMENTAL
Intervention: Comorbid moderate-to-severe SDB and AF
Number of subjects: 353

Group type: COMPARATOR
Intervention: AF without moderate-to-severe SDB
Number of subjects: 353
Study: 38275116

Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Number of subjects: 1577

Group type: COMPARATOR
Intervention: Intravenous alteplase
Number of subjects: 1577
Study: 38275650

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 183

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 183
Study: 38276920

Group type: EXPERIMENTAL
Intervention: Self-reported fair or poor oral health
Number of subjects: 2
Study: 38276933

Group type: EXPERIMENTAL
Intervention: Extracorporeal perfusion system
Number of subjects: 173
Study: 38277156

Group type: EXPERIMENTAL
Intervention: Omnipod insulin delivery system
Number of subjects: 0
Study: 38277161

Group type: EXPERIMENTAL
Intervention: Neural-Net Artificial Pancreas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38277162

Group type: EXPERIMENTAL
Intervention: Macronutrient Intake and Number of Meals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38277197

Group type: EXPERIMENTAL
Intervention: Powered ankle-foot device with device-specific rehabilitation intervention (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Powered ankle-foot device with current standard of practice (Group B)
Number of subjects: 30
Study: 38277204

Group type: EXPERIMENTAL
Intervention: Primary Prevention of Posttraumatic Stress Disorder in Military Professionals (PREPARE) program, structured into 8 workshops and 2 debriefing and practice reinforcement workshops.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (nonintervention group).
Number of subjects: 0
Study: 38277210

Group type: EXPERIMENTAL
Intervention: Active stimulation (cTBS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 38277468

Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 10584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10584
Study: 38277619

Group type: EXPERIMENTAL
Intervention: Azacitidine, Venetoclax, and Gilteritinib
Number of subjects: 52

Group type: COMPARATOR
Intervention: Azacitidine plus Venetoclax (standard of care)
Number of subjects: 52
Study: 38277865

Group type: EXPERIMENTAL
Intervention: ALIS + GBT
Number of subjects: 48

Group type: COMPARATOR
Intervention: GBT alone
Number of subjects: 48
Study: 38277979

Group type: EXPERIMENTAL
Intervention: Gynaecological follow-up
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Annual cervical screening
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Papillomavirus vaccination
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Contraceptive use
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Unplanned pregnancies
Number of subjects: 192
Study: 38278170

Group type: EXPERIMENTAL
Intervention: Pozelimab (30 mg/kg loading dose, followed by weekly subcutaneous doses based on body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pozelimab
Number of subjects: 10
Study: 38278217

Group type: EXPERIMENTAL
Intervention: Nighttime pistachio snack (57 g/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care (education to consume 1-2 carbohydrate exchanges)
Number of subjects: 66
Study: 38278357

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 100
Study: 38278364

Group type: EXPERIMENTAL
Intervention: Plant stanol ester (4 g/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 38278365

Group type: EXPERIMENTAL
Intervention: Fast-food dietary pattern (36%)
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Western contemporary dietary pattern (30%)
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Plant-based dietary pattern (20%)
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Animal-based dietary pattern (14%)
Number of subjects: 3022

Group type: COMPARATOR
Intervention: Plant-based dietary pattern (38%)
Number of subjects: 3022

Group type: COMPARATOR
Intervention: Fast-food dietary pattern (29%)
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Fast-food pattern
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Animal-based diet
Number of subjects: 3022

Group type: EXPERIMENTAL
Intervention: Fast-food, Western contemporary, or animal-based diet
Number of subjects: 3022
Study: 38278478

Group type: EXPERIMENTAL
Intervention: eSOC+FBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: eSOC
Number of subjects: 0
Study: 38278503

Group type: EXPERIMENTAL
Intervention: Intracoronary electrocardiogram (icECG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Doppler derived CMD indices (CFR and HMR)
Number of subjects: 21
Study: 38278747

Group type: EXPERIMENTAL
Intervention: Fever management video training
Number of subjects: 99
Study: 38278856

Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis (LVA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conservative therapy (CDT)
Number of subjects: 92
Study: 38278871

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 156
Study: 38278960

Group type: EXPERIMENTAL
Intervention: Dasatinib for 2 years after re-treatment
Number of subjects: 94
Study: 38279085

Group type: EXPERIMENTAL
Intervention: Psilocybin (30 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Active placebo (5 mg)
Number of subjects: 62
Study: 38279109

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 20
Study: 38279124

Group type: EXPERIMENTAL
Intervention: DON 0.1 mg/kg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DON 1.0 mg/kg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 38279131

Group type: EXPERIMENTAL
Intervention: Get Back digital programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 38279164

Group type: EXPERIMENTAL
Intervention: MRSA infection
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: LAMP assay for MRSA detection
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: S. aureus infection
Number of subjects: 522
Study: 38279175

Group type: EXPERIMENTAL
Intervention: Consistently unhealthy lifestyle group
Number of subjects: 546

Group type: COMPARATOR
Intervention: Mixed pattern group
Number of subjects: 546

Group type: COMPARATOR
Intervention: Consistently healthy group
Number of subjects: 546
Study: 38279184

Group type: EXPERIMENTAL
Intervention: far-UVC light devices (222 nm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo light devices (400-700 nm)
Number of subjects: 0
Study: 38279199

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program, eight sessions over 4 weeks (two sessions per week)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Deep relaxation exercises, four times a week for 4 weeks using deep relaxation videos
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group receiving routine prenatal care
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Number of subjects: 95
Study: 38279363

Group type: EXPERIMENTAL
Intervention: Otilimab 180 mg subcutaneously once weekly for 5 weeks, then every other week until week 10.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 38279364

Group type: EXPERIMENTAL
Intervention: Otilimab 22.5 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Otilimab 45 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Otilimab 90 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Otilimab 135 mg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Otilimab 180 mg
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 38279367

Group type: EXPERIMENTAL
Intervention: 150 mg of subcutaneous anifrolumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 mg of subcutaneous anifrolumab
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 38279368

Group type: EXPERIMENTAL
Intervention: Intravenous belimumab (10 mg/kg)
Number of subjects: 4018

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4018
Study: 38279383

Group type: EXPERIMENTAL
Intervention: PF-06826647 400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PF-06826647 100 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 38279390

Group type: EXPERIMENTAL
Intervention: Tocilizumab once a week
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Tocilizumab every other week
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo with 26-week prednisone taper
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo with 52-week prednisone taper
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Tocilizumab alone
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus glucocorticoids
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Glucocorticoids alone
Number of subjects: 215
Study: 38279402

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 intravenously)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 56
Study: 38279410

Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation device for up to 30 min per day, delivering pulses of 20 kHz
Number of subjects: 30
Study: 38279411

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg or 10 mg twice daily
Number of subjects: 686
Study: 38279575

Group type: EXPERIMENTAL
Intervention: Piclidenoson 3 mg BID
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Piclidenoson 2 mg BID
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 38279662

Group type: EXPERIMENTAL
Intervention: MDMA 0.75 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDMA 1.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methamphetamine (MA) 20 mg
Number of subjects: 0
Study: 38279910

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with Timothy grass (SCIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCIT + Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38280003

Group type: EXPERIMENTAL
Intervention: AK104 (Cadonilimab) therapy
Number of subjects: 21
Study: 38280022

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH) and whole-body vibration (WBV) training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normoxia and non-exercise (Control)
Number of subjects: 60
Study: 38280052

Group type: EXPERIMENTAL
Intervention: Nanoemulsion curcumin (NEC, 200 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 38280066

Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 25

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rHuEPO)
Number of subjects: 25
Study: 38280118

Group type: EXPERIMENTAL
Intervention: High tone therapy (HiToP 191 PNP ®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open-label HiToP PNP ® device (after opt-in)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical application observation group (not specified if treated with HiToP or other)
Number of subjects: 0
Study: 38280124

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (6-month multifaceted program focused on behavioral changes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 80
Study: 38280181

Group type: EXPERIMENTAL
Intervention: Carboplatin, etoposide, and atezolizumab
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Atezolizumab maintenance therapy
Number of subjects: 403
Study: 38280218

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study: 38280281

Group type: EXPERIMENTAL
Intervention: Short-acting bronchodilator (SAB) - 400 µg of salbutamol and 80 µg of ipratropium
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Short-acting bronchodilator (SAB)
Number of subjects: 22
Study: 38280387

Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing (scRNA-seq)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage NET analyses
Number of subjects: 39
Study: 38280392

Group type: EXPERIMENTAL
Intervention: Laquinimod 1.0 mg
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 38280448

Group type: EXPERIMENTAL
Intervention: Iruplinalkib 180 mg once daily (7-day run-in at 60 mg once daily)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Iruplinalkib
Number of subjects: 292

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 292
Study: 38280483

Group type: EXPERIMENTAL
Intervention: Inpatient integrated palliative and transplant care
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 38280531

Group type: EXPERIMENTAL
Intervention: Duodenal mucosal resurfacing (DMR)
Number of subjects: 28
Study: 38280532

Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR) with re-excision of incomplete mucosal layer excision (IME)
Number of subjects: 508
Study: 38280653

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg every 4 weeks for 24 weeks
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 4 weeks for 24 weeks
Number of subjects: 1282
Study: 38280834

Group type: EXPERIMENTAL
Intervention: High socioeconomic status (SES)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: High lifestyle score
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle score
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Joint effect of SES and lifestyle factors
Number of subjects: 773
Study: 38281006

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (IMV) for ≥ 96 hours
Number of subjects: 7758

Group type: EXPERIMENTAL
Intervention: Independent risk factors identified
Number of subjects: 7758